Drugs / HRS-4642
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05533463 | Sep 2022 → Jun 2024 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/26 trials · 1 met primary | ||||||
| Phase 1/2 | NCT07806058 | Sep 2026 → Dec 2028 expected | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06955390 | May → Dec 2025 overdue | cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06773130 | Feb 2025 → Aug 2026 overdue | pancreatic ductal adenocarcinoma | West China Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06520488 | Aug 2024 → Mar 2027 expected | cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | Met primary |
| Phase 1/2 | NCT06385678 | Jul 2024 → Dec 2025 overdue | — | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06427239 | Jun 2024 → Jun 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT07691593 | Jun 2026 → Oct 2027 expected | malignant pancreatic neoplasm | Changhai Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07503639 | Apr 2026 → Apr 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07240766 | Feb 2026 → May 2027 expected | adenocarcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07438106 | Jan 2026 → Oct 2027 expected | — | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07131514 | Aug 2025 → Jun 2027 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06938282 | May 2025 → Apr 2027 expected | malignant pancreatic neoplasm | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06770452 | Mar 2025 → Feb 2027 expected | carcinoma | Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06587061 | Dec 2024 → Jun 2027 expected | malignant pancreatic neoplasm | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06620848 | Nov 2024 → Dec 2026 expected | biliary tract cancer | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06547736 | Oct 2024 → Mar 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07232875 | Nov 2025 → Apr 2029 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07296341 Comparator | Jan 2026 → Oct 2027 expected | — | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-4642 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07691593 ↗ |
| Known as | HRS-4642 Injection | “HRS-4642 Injection: 500 mg intravenous infusion on Day 1, and 1200 mg intravenous infusion on Day 8, every 3 weeks per cycle.” NCT07240766 ↗ |
| Action | Inhibit | “HRS-4642 is a new, high‑affinity, noncovalent KRAS-G12D inhibitor.” PMID 42426224 ↗ Jul 2026 |
| Route | Intravenous | “Formulated as a liposomal nanoparticle for intravenous administration” PMID 42426224 ↗ Jul 2026 |
| Target | KRAS | “HRS-4642 is a new, high‑affinity, noncovalent KRAS-G12D inhibitor.” PMID 42426224 ↗ Jul 2026 |